In phase II trials, Bapineuzumab administration reduced Aβ plaques in AD brains (Salloway et al., 2009; Rinne et al., 2010) and was associated with decreased total and phospho-tau levels in the CSF (Asuni et al., 2007). This evidence concerns the gene MAPT and Alzheimer disease.